Nektar Therapeutics
NKTR Real Time Price USDRecent trades of NKTR by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NKTR holdings by institutional investors
Quarterly net insider trading by NKTR's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$50,000 Jan 20, 2022 Issue: Health Issues
-
$50,000 Oct 20, 2021 Issue: Health Issues
-
$50,000 Jul 20, 2021 Issue: Health Issues
-
$50,000 Apr 20, 2021 Issue: Health Issues
-
$50,000 Jan 21, 2021 Issue: Health Issues
-
$50,000 Oct 20, 2020 Issue: Health Issues
-
$60,000 Jul 20, 2020 Issue: Health Issues
-
$14,000 Jul 20, 2020 Issue: Pharmacy
-
$60,000 Apr 26, 2020 Issue: Health Issues
-
$60,000 Feb 25, 2020 Issue: Health Issues
-
$50,000 Jan 21, 2020 Issue: Health Issues
-
$14,000 Jan 15, 2020 Issue: Pharmacy
-
$20,000 Jan 10, 2020 Issue: Pharmacy
-
$20,000 Oct 16, 2019 Issue: Pharmacy
-
$50,000 Oct 08, 2019 Issue: Health Issues
-
$50,000 Jul 18, 2019 Issue: Health Issues
-
$20,000 Jul 15, 2019 Issue: Pharmacy
-
$50,000 Apr 12, 2019 Issue: Health Issues
-
$20,000 Apr 11, 2019 Issue: Pharmacy
-
$50,000 Jan 20, 2019 Issue: Health Issues
-
$20,000 Jan 18, 2019 Issue: Pharmacy
-
$20,000 Oct 18, 2018 Issue: Pharmacy
-
$50,000 Oct 16, 2018 Issue: Health Issues
-
$108,000 Oct 16, 2018 Issue: Pharmacy
-
$20,000 Jul 20, 2018 Issue: Taxation/Internal Revenue Code Pharmacy
-
$50,000 Jul 20, 2018 Issue: Health Issues
-
$21,600 Jul 18, 2018 Issue: Pharmacy
-
$20,000 Apr 20, 2018 Issue: Taxation/Internal Revenue Code Pharmacy
-
$60,000 Apr 18, 2018 Issue: Health Issues
-
$72,000 Apr 17, 2018 Issue: Pharmacy
-
$20,000 Jan 22, 2018 Issue: Taxation/Internal Revenue Code Pharmacy
-
$144,000 Jan 19, 2018 Issue: Pharmacy
-
$30,000 Jan 18, 2018 Issue: Health Issues
-
$20,000 Oct 20, 2017 Issue: Taxation/Internal Revenue Code Pharmacy
-
$20,000 Oct 20, 2017 Issue: Pharmacy
-
$30,000 Oct 13, 2017 Issue: Health Issues
-
$20,000 Apr 20, 2017 Issue: Pharmacy
-
$60,000 Apr 01, 2017 Issue: Pharmacy
-
$20,000 Jan 23, 2017 Issue: Pharmacy
-
$60,000 Jan 19, 2017 Issue: Pharmacy
-
$20,000 Oct 20, 2016 Issue: Pharmacy
-
$60,000 Oct 20, 2016 Issue: Pharmacy
-
$20,000 Jul 20, 2016 Issue: Pharmacy
-
$60,000 Jul 20, 2016 Issue: Pharmacy
-
$20,000 Apr 20, 2016 Issue: Pharmacy
-
$60,000 Apr 20, 2016 Issue: Pharmacy
-
$10,000 Jan 20, 2016 Issue: Pharmacy
-
$90,000 Jan 20, 2016 Issue: Pharmacy
-
$90,000 Oct 20, 2015 Issue: Pharmacy
-
$90,000 Jul 20, 2015 Issue: Pharmacy
-
$90,000 Apr 20, 2015 Issue: Pharmacy
-
$100,000 Jan 20, 2015 Issue: Pharmacy
-
$90,000 Oct 20, 2014 Issue: Pharmacy
-
$90,000 Jul 21, 2014 Issue: Pharmacy
-
$10,000 Oct 01, 2008 Issue: Health Issues
-
$10,000 Jul 18, 2008 Issue: Health Issues
Former government officials who have lobbied for NKTR
13 former government officials from 7 congressional offices at 5 lobbying firms have lobbied for NKTR, most recently Jul 15, 2022.
-
Brent Del Monte Other See prior filing
-
John Stone Other See prior filing
-
Remy Mason Other See prior filing
-
Daniel Farmer Other See prior filing
-
Robb Walton Other See prior filing
-
Joel Bailey Other See prior filing
-
Matt Hoffmann Other See prior filing
-
Jack Quinn Other Dep. COS and Counselor to the Vice President, COS to the VP and Assistant to President, Counsel to the President
NKTR Estimated quarterly lobbying spending
NKTR Revenue by Segment or Geography
New NKTR patent grants
-
Patent Title: Stabilized polymeric thiol reagents Apr. 12, 2016
-
Patent Title: Polymer derivatives comprising an acetal or ketal branching point Apr. 12, 2016
-
Patent Title: Identifying dry nebulizer elements Mar. 01, 2016
-
Patent Title: Oligomer-containing substituted aromatic triazine compounds Feb. 23, 2016
-
Patent Title: Aerosolization device Jan. 26, 2016
-
Patent Title: Oligomer-nitroimidazole anti-infective conjugates Jan. 12, 2016
-
Patent Title: Oligomer-bis-chromonyl compound conjugates Jan. 12, 2016
-
Patent Title: Oligomer-opioid agonist conjugates Jan. 12, 2016
-
Patent Title: Oligomer-opioid agonist conjugates Jan. 12, 2016
-
Patent Title: Oligomer-aryloxy-substituted propanamine conjugates Jan. 12, 2016
-
Patent Title: Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method Jan. 05, 2016
-
Patent Title: N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides Jan. 05, 2016
-
Patent Title: Oligomer modified diaromatic substituted compounds Jan. 05, 2016
-
Patent Title: Salt form of a multi-arm polymer-drug conjugate Jan. 05, 2016
-
Patent Title: Non-ring hydroxy substituted taxanes and methods for synthesizing the same Dec. 01, 2015
-
Patent Title: Oligomer-amino acid conjugates Nov. 24, 2015
-
Patent Title: Branched polymers Nov. 17, 2015
-
Patent Title: Carbohydrate-based drug delivery polymers and conjugates thereof Nov. 03, 2015
-
Patent Title: Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom Nov. 03, 2015
-
Patent Title: N-maleimidyl polymer derivatives Oct. 27, 2015
-
Patent Title: Oligomer-dantrolene conjugates and related compounds Oct. 27, 2015
-
Patent Title: Oligomer-cannabinoid conjugates Oct. 13, 2015
-
Patent Title: Systems and methods for driving sealed nebulizers Oct. 06, 2015
-
Patent Title: Oligomer conjugates of heteropentacyclic nucleosides Oct. 06, 2015
-
Patent Title: Aerosolization device Sep. 29, 2015
-
Patent Title: Oligomer-calcium channel blocker conjugates Sep. 15, 2015
-
Patent Title: Oligomer-anticholinergic agent conjugates Sep. 08, 2015
-
Patent Title: Compositions of particulate coformulation Sep. 01, 2015
-
Patent Title: Vibration systems and methods Aug. 18, 2015
-
Patent Title: Oligomer-protease inhibitor conjugates Aug. 18, 2015
-
Patent Title: Conjugates of an anti-tnf-α antibody Aug. 11, 2015
-
Patent Title: Oligomer-containing pyrrolidine compounds Aug. 04, 2015
-
Patent Title: Oligomer-protein tyrosine kinase inhibitor conjugates Aug. 04, 2015
-
Patent Title: Oligome-bis-chromonyl compound conjugates Aug. 04, 2015
-
Patent Title: Reagents Aug. 04, 2015
-
Patent Title: Methods for preparing polymeric reagents Jul. 28, 2015
-
Patent Title: Hydroxylated tricyclic compounds Jul. 28, 2015
-
Patent Title: Complexes of small-interfering nucleic acids Jul. 28, 2015
-
Patent Title: Polymer derivatives comprising an imide branching point Jul. 21, 2015
-
Patent Title: Negatively biased sealed nebulizers systems and methods Jul. 21, 2015
-
Patent Title: Oligomer-protein tyrosine kinase inhibitor conjugates Jul. 21, 2015
-
Patent Title: Oligomer-diarylpiperazine conjugates Jun. 23, 2015
-
Patent Title: Orthoester compound Jun. 02, 2015
-
Patent Title: Pharmaceutical compositions of conjugates formed from polymer derivatives having particular atom arrangements Jun. 02, 2015
-
Patent Title: Thiol-selective water-soluble polymer derivatives May. 26, 2015
-
Patent Title: Hydrolytically degradable alkylene oxide based polymers May. 26, 2015
-
Patent Title: Oligomer-foscarnet conjugates Apr. 14, 2015
-
Patent Title: N-maleimidyl polymer derivatives Mar. 31, 2015
-
Patent Title: Multi-arm polymeric alkanoate conjugates Feb. 24, 2015
-
Patent Title: Oligomer-opioid agonist conjugates Feb. 10, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NKTR from public contracts
Recent insights relating to NKTR
Recent picks made for NKTR stock on CNBC
ETFs with the largest estimated holdings in NKTR
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NKTR stock a Buy, Sell, or Hold?
- What is the price target for $NKTR stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NKTR stock?
- Who owns the most shares of $NKTR stock?
- What funds own $NKTR stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NKTR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
- Address San Francisco, CA
- Market Cap 1.2 billion
- Employees 63
- Industrial Classification Pharmaceutical Preparations
Nektar Therapeutics (NKTR) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Nektar Therapeutics (NKTR).
Quiver Premium charts NKTR's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at NKTR, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|